The latest data from the Hong Kong Stock Exchange reveals that on January 7, a shareholder of MEDSCI (02415) transferred shares from Merrill Lynch Far East Limited to China International Capital Corporation Hong Kong Securities. The transferred shares had a market value of HK$88.2108 million, representing 10.53% of the company's stock. The company's previously released interim results for 2025 showed revenue of RMB 125 million, a year-on-year increase of 13.2%. Net profit reached RMB 13.239 million, surging by an impressive 5238.3% compared to the same period last year. Basic earnings per share were RMB 2.45 cents, and the company proposed an interim dividend of HK 1.1 cent per share. The increase in total revenue during the period was primarily driven by a recovery in the pharmaceutical industry and the accelerated transition of domestic pharmaceutical companies towards evidence-driven marketing models, which fueled demand for precision omnichannel marketing solutions.